# A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

> **NCT02482298** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 87 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Ticagrelor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02482298
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-09
- **Primary completion:** 2016-11-16
- **Final completion:** 2016-11-16
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482298, "A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02482298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*